Cinqair (reslizumab) is a monoclonal antibody that helps the body’s immune system by reducing the level of a certain type of white blood cells. Specifically it is an interleukin- 5 (IL-5) antagonist monoclonal antibody for add-on maintenance treatment of patients with severe asthma aged 18 years and older and with an eosinophilic phenotype.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
Teva Pharmaceutical Industries
Biologics (IL 5 antagonist monoclonal antibodies)
WHAT IT TREATS:
Severe poorly controlled asthma
Every 4 weeks
Length of infusion:
20 to 50 minutes plus an observation period of 30 minutes
FOR MORE INFORMATION: